Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 11.02.2019 1 Ann Oncol 2 Ann Surg Oncol 3 Anticancer Res 4 BMC Cancer 1 Br J Cancer 1 Breast Cancer 2 Breast Cancer (Auckl) 1 Breast Cancer (Dove Med Press) 4 Breast Cancer Res 9 Breast Cancer Res Treat 3 Breast J 3 Cancer 1 Cancer Lett 1 Cancer Res 1 Carcinogenesis 1 Clin Breast Cancer 3 Clin Cancer Res 1 Eur J Cancer 2 Eur J Surg Oncol 1 Eur Radiol 5 Int J Cancer 2 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 3 J Natl Cancer Inst 1 J Nucl Med 1 J Surg Oncol 3 Lancet Oncol 1 NPJ Breast Cancer 2 Oncogene 1 Oncol Rep 1 Oncology (Williston Park) 1 PLoS One 4 Proc Natl Acad Sci U S A 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. CONDORELLI R, Mosele F, Verret B, Bachelot T, et al
   Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
   Ann Oncol. 2019 Jan 31. pii: 5305018. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

2. WANG M, Wu K, Chen H
   ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2019 Jan 31. pii: 10.1245/s10434-019-07198.
   PubMed     Text format    
   
   
3. SELLA T, Partridge AH
   Reproductive Health Issues for Young Women with Breast Cancer: Emerging Strategies for Difficult Situations.
   Ann Surg Oncol. 2019 Feb 1. pii: 10.1245/s10434-019-07205.
   PubMed     Text format    
   
   

   
   Anticancer Res

4. LEE SJ, Jeong JH, Lee IH, Lee J, et al
   Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
   Anticancer Res. 2019;39:751-758.
   PubMed     Text format     Abstract available
   
   
5. SONNENBLICK A, Bailey A, Uziely B, Untch M, et al
   Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
   Anticancer Res. 2019;39:797-802.
   PubMed     Text format     Abstract available
   
   
6. SEKI T, Liu J, Brutkiewicz RR, Tsuji M, et al
   A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
   Anticancer Res. 2019;39:549-555.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

7. GALLARDO-ALVARADO LN, Tusie-Luna MT, Tussie-Luna MI, Diaz-Chavez J, et al
   Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
   BMC Cancer. 2019;19:118.
   PubMed     Text format     Abstract available
   
   
8. KONIG L, Mairinger FD, Hoffmann O, Bittner AK, et al
   Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
   BMC Cancer. 2019;19:120.
   PubMed     Text format     Abstract available
   
   
9. KAHAN Z, Grecea D, Smakal M, Tjulandin S, et al
   Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
   BMC Cancer. 2019;19:122.
   PubMed     Text format     Abstract available
   
   
10. WANG L, Liu L, Lou Z, Ding L, et al
    Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
    BMC Cancer. 2019;19:128.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

11. METCALFE K, Lynch HT, Foulkes WD, Tung N, et al
    Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    Br J Cancer. 2019 Feb 6. pii: 10.1038/s41416-019-0376.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

12. ISHIGURO H, Ohno S, Yamamoto Y, Takao S, et al
    Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
    Breast Cancer. 2019 Feb 7. pii: 10.1007/s12282-019-00952.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Auckl)

13. KIKAWA Y, Kotake T, Kajiwara Y, Hashimoto K, et al
    Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.
    Breast Cancer (Auckl). 2019;13:1178223418825135.
    PubMed     Text format     Abstract available
    
    
14. LEE J, Oh M, Ko S, Park C, et al
    Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea.
    Breast Cancer (Auckl). 2019;13:1178223418825134.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

15. DE SILVA S, Tennekoon KH, Karunanayake EH
    Overview of the genetic basis toward early detection of breast cancer.
    Breast Cancer (Dove Med Press). 2019;11:71-80.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

16. GAMPENRIEDER SP, Peer A, Weismann C, Meissnitzer M, et al
    Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Breast Cancer Res. 2019;21:19.
    PubMed     Text format     Abstract available
    
    
17. WANG DY, Gendoo DMA, Ben-David Y, Woodgett JR, et al
    A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Breast Cancer Res. 2019;21:18.
    PubMed     Text format     Abstract available
    
    
18. SCHWARZENBACHER D, Klec C, Pasculli B, Cerk S, et al
    MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Breast Cancer Res. 2019;21:20.
    PubMed     Text format     Abstract available
    
    
19. RODRIGUEZ-MARTINEZ A, de Miguel-Perez D, Ortega FG, Garcia-Puche JL, et al
    Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:21.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

20. ALTUNDAG K
    HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
    Breast Cancer Res Treat. 2019 Feb 1. pii: 10.1007/s10549-019-05151.
    PubMed     Text format    
    
    
21. LIGABUE MB, Campanini I, Veroni P, Cepelli A, et al
    Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05136.
    PubMed     Text format     Abstract available
    
    
22. SUN M, Wu D, Zhou K, Li H, et al
    An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Breast Cancer Res Treat. 2019 Feb 4. pii: 10.1007/s10549-019-05147.
    PubMed     Text format     Abstract available
    
    
23. LIU ZH, Wang K, Lin DY, Xu J, et al
    Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05148.
    PubMed     Text format     Abstract available
    
    
24. DICKINSON SL, Golzarri-Arroyo L, Brown AW, McComb B, et al
    Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEA
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05155.
    PubMed     Text format    
    
    
25. HUSSAIN Y, Drill E, Dang CT, Liu JE, et al
    Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05139.
    PubMed     Text format     Abstract available
    
    
26. LIU Y, Pandey PR, Sharma S, Xing F, et al
    ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-018-05126.
    PubMed     Text format     Abstract available
    
    
27. BICK U, Engel C, Krug B, Heindel W, et al
    High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05152.
    PubMed     Text format     Abstract available
    
    
28. O'MEARA T, Safonov A, Casadevall D, Qing T, et al
    Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05156.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

29. MANSO L, Moreno Anton F, Izarzugaza Peron Y, Delgado Mingorance JI, et al
    Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
    Breast J. 2019 Feb 8. doi: 10.1111/tbj.13199.
    PubMed     Text format     Abstract available
    
    
30. CERBELLI B, Botticelli A, Pisano A, Campagna D, et al
    Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?
    Breast J. 2019 Feb 7. doi: 10.1111/tbj.13206.
    PubMed     Text format     Abstract available
    
    
31. JUNG N, Kim HJ, Jung JH, Lee SW, et al
    Restaging the axilla after neo-adjuvant chemotherapy for breast cancer: Predictive factors for residual metastatic lymph node disease with negative imaging findings.
    Breast J. 2019 Feb 3. doi: 10.1111/tbj.13192.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

32. PARTRIDGE AH, Ruddy KJ, Barry WT, Greaney ML, et al
    A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31984.
    PubMed     Text format     Abstract available
    
    
33. EUHUS DM, Addae JK, Snyder CF, Canner JK, et al
    Change in health-related quality of life in older women after diagnosis of a small breast cancer.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31993.
    PubMed     Text format     Abstract available
    
    
34. WALLNER LP, Li Y, McLeod MC, Gargaro J, et al
    Primary care provider-reported involvement in breast cancer treatment decisions.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31998.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

35. FU S, Chen X, Lo HW, Lin J, et al
    Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Cancer Lett. 2019 Jan 29. pii: S0304-3835(19)30046.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

36. SHINDE A, Hardy SD, Kim D, Akhand SS, et al
    Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2636.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

37. SENTHIL KUMAR KJ, Gokila Vani M, Hsieh HW, Lin CC, et al
    MicroRNA-708 activation by glucocorticoid receptor agonists regulate breast cancer tumorigenesis and metastasis via downregulation of NF-kappaB signaling.
    Carcinogenesis. 2019 Feb 1. pii: 5307244. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

38. DENG K, Mo S, Liu X, Chen J, et al
    Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer.
    Clin Breast Cancer. 2018 Dec 12. pii: S1526-8209(18)30645.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

39. ZINGER L, Merenbakh-Lamin K, Klein Goldberg A, Elazar A, et al
    Ligand binding domain activating mutations of ESR1 rewire cellular metabolism of breast cancer cells.
    Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-1505.
    PubMed     Text format     Abstract available
    
    
40. NAKSHATRI H, Kumar B, Burney HN, Cox ML, et al
    Genetic ancestry-dependent differences in breast cancer-induced field defects in the tumor-adjacent normal breast.
    Clin Cancer Res. 2019 Feb 4. pii: 1078-0432.CCR-18-3427.
    PubMed     Text format     Abstract available
    
    
41. MAYER IA, Prat A, Egle D, Blau S, et al
    A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
    Clin Cancer Res. 2019 Feb 5. pii: 1078-0432.CCR-18-3160.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

42. MONTEMURRO F, Ellis P, Anton A, Wuerstlein R, et al
    Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Eur J Cancer. 2019;109:92-102.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

43. SORAN A
    Are we close to the end of the primary tumor resection discussion for de novo stage IV BC?
    Eur J Surg Oncol. 2019;45:81-82.
    PubMed     Text format    
    
    
44. VANE MLG, van Nijnatten TJA, Nelemans PJ, Lobbes MBI, et al
    Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
    Eur J Surg Oncol. 2019 Jan 14. pii: S0748-7983(19)30035.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

45. BLANKS RG, Given-Wilson RM, Cohen SL, Patnick J, et al
    An analysis of 11.3 million screening tests examining the association between recall and cancer detection rates in the English NHS breast cancer screening programme.
    Eur Radiol. 2019 Feb 4. pii: 10.1007/s00330-018-5957.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

46. ZEINOMAR N, Phillips KA, Daly MB, Milne RL, et al
    Benign Breast Disease Increases Breast Cancer Risk Independent of Underlying Familial Risk Profile: Findings from a Prospective Family Study Cohort (ProF-SC).
    Int J Cancer. 2019 Feb 6. doi: 10.1002/ijc.32112.
    PubMed     Text format     Abstract available
    
    
47. BARNAWI R, Al-Khaldi S, Colak D, Tulbah A, et al
    beta1 Integrin is Essential for Fascin-Mediated Breast Cancer Stem Cell Function and Disease Progression.
    Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32183.
    PubMed     Text format     Abstract available
    
    
48. SUN W, Xu X, Jiang Y, Jin X, et al
    Transcriptome analysis of Luminal Breast Cancer Reveals a Role for LOL in Tumor Progression and Tamoxifen Resistance.
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32185.
    PubMed     Text format     Abstract available
    
    
49. KIM JY, Lee E, Park K, Jung HH, et al
    Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-po
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32188.
    PubMed     Text format     Abstract available
    
    
50. DENG M, Chen HH, Zhu X, Luo M, et al
    Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32184.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

51. GURDAL H, Tuglu MM, Bostanabad SY, Dalkilic B, et al
    Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triplenegative breast cancer cell lines.
    Int J Oncol. 2019 Jan 28. doi: 10.3892/ijo.2019.4697.
    PubMed     Text format     Abstract available
    
    
52. CHEN P, Yue X, Xiong H, Lu X, et al
    RBM3 upregulates ARPC2 by binding the 3'UTR and contributes to breast cancer progression.
    Int J Oncol. 2019 Jan 28. doi: 10.3892/ijo.2019.4698.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

53. ADVANI PG, Lei X, Swanick CW, Xu Y, et al
    Local-therapy decisional regret in older women with breast cancer: A population-based study.
    Int J Radiat Oncol Biol Phys. 2019 Feb 1. pii: S0360-3016(19)30180.
    PubMed     Text format     Abstract available
    
    
54. BERGOM C, Vogel WV
    Image Guided Evolution of Nodal Contouring Guidelines in Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2019;103:592-594.
    PubMed     Text format    
    
    

    
    J Clin Oncol

55. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

56. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    PubMed     Text format    
    
    
57. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
58. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    PubMed     Text format    
    
    

    
    J Nucl Med

59. LAFFON E, Marthan R
    Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Feb 7. pii: jnumed.119.226092. doi: 10.2967/jnumed.119.226092.
    PubMed     Text format    
    
    

    
    J Surg Oncol

60. TAN MG, Isaranuwatchai W, DeLyzer T, Butler K, et al
    A cost-effectiveness analysis of DIEP vs free MS-TRAM flap for microsurgical breast reconstruction.
    J Surg Oncol. 2019;119:388-396.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

61. SAAD ED, Squifflet P, Burzykowski T, Quinaux E, et al
    Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30750.
    PubMed     Text format     Abstract available
    
    
62. AMIR E
    Endpoint selection in HER2-positive early breast cancer.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30779.
    PubMed     Text format    
    
    
63. WANG SL, Fang H, Song YW, Wang WH, et al
    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Lancet Oncol. 2019 Jan 30. pii: S1470-2045(18)30813.
    PubMed     Text format     Abstract available
    
    

    
    NPJ Breast Cancer

64. SONNENBLICK A, Venet D, Brohee S, Ponde N, et al
    pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.
    NPJ Breast Cancer. 2019;5:7.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

65. KANG MH, Jeong KJ, Kim WY, Lee HJ, et al
    Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.
    Oncogene. 2019 Feb 4. pii: 10.1038/s41388-019-0721.
    PubMed     Text format     Abstract available
    
    
66. CASTAGNOLI L, Cancila V, Cordoba-Romero SL, Faraci S, et al
    WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
    Oncogene. 2019 Jan 31. pii: 10.1038/s41388-019-0700.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

67. GUTTLER A, Theuerkorn K, Riemann A, Wichmann H, et al
    Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
    Oncol Rep. 2019 Feb 5. doi: 10.3892/or.2019.7001.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

68. WAPNIR IL, Khan A
    Current Strategies for the Management of Locoregional Breast Cancer Recurrence.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

69. HEBERT-MAGEE S, Yu H, Behring M, Jadhav T, et al
    The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype.
    PLoS One. 2019;14:e0211734.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

70. LI X, Gruosso T, Zuo D, Omeroglu A, et al
    Infiltration of CD8(+) T cells into tumor cell clusters in triple-negative breast cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 7. pii: 1817652116.
    PubMed     Text format     Abstract available
    
    
71. TOKUYAMA M, Kong Y, Song E, Jayewickreme T, et al
    ERVmap analysis reveals genome-wide transcription of human endogenous retroviruses.
    Proc Natl Acad Sci U S A. 2018;115:12565-12572.
    PubMed     Text format     Abstract available
    
    
72. KUBLI SP, Bassi C, Roux C, Wakeham A, et al
    AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 7. pii: 1815126116.
    PubMed     Text format     Abstract available
    
    
73. BLASCO-BENITO S, Moreno E, Seijo-Vila M, Tundidor I, et al
    Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer.
    Proc Natl Acad Sci U S A. 2019 Feb 7. pii: 1815034116.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

74. MAURI G, Sconfienza LM, Sardanelli F
    Imaging-guided Percutaneous Ablation: A Step Forward to Minimize the Invasiveness of Breast Cancer Treatment.
    Radiology. 2019 Feb 5:182448. doi: 10.1148/radiol.2019182448.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: